Emergent BioSolutions (EBS) Change in Account Payables (2010 - 2026)

Emergent BioSolutions' Change in Account Payables history runs 17 years deep, the most recent figure standing at -$14.4 million for Q1 2026.

• On a quarterly basis, Change in Account Payables fell 166.67% year-over-year to -$14.4 million in Q1 2026; TTM through Mar 2026 was -$17.4 million, a 51.67% increase from a year earlier, with the FY2025 full-year figure at -$8.4 million, up 74.55% from the prior year.
• Change in Account Payables slipped to -$14.4 million in Q1 2026 per EBS's latest filing, from $11.4 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $31.0 million in Q1 2023 and bottomed at -$23.0 million in Q3 2024.
• The 5-year median for Change in Account Payables is -$4.2 million (2022), against an average of -$3.5 million.
• Across the five-year window, Change in Account Payables jumped 310.88% in 2023 and slumped 500.0% in 2025, its largest moves.
• Year by year, Change in Account Payables stood at -$2.2 million in 2022, then sank by 222.73% to -$7.1 million in 2023, then plunged by 43.66% to -$10.2 million in 2024, then soared by 211.76% to $11.4 million in 2025, then sank by 226.32% to -$14.4 million in 2026.
• Per Business Quant, the three latest EBS Change in Account Payables figures stand at -$14.4 million (Q1 2026), $11.4 million (Q4 2025), and -$4.0 million (Q3 2025).